Q3 2025 Lisata Therapeutics Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: $2.35 (+0.43%)

Transcript 10-Q8-K

Key Points

Positve

Lisata Therapeutics Inc (LSTA) achieved several development milestones with their product candidate certepetide, showing positive preliminary results in multiple studies.
The company entered into a strategic alliance with GATC Health to leverage AI technology for drug discovery, enhancing their development capabilities.
Lisata Therapeutics Inc (LSTA) executed a non-exclusive global license agreement with Catalan, allowing Catalan to use certepetide in their Smart Tag ADC technology platform.
Operating expenses decreased by 17.3% year-over-year, demonstrating effective cost management.
The company has cash and cash equivalents of approximately $19 million, projected to support operations into the first quarter of 2027.

Negative

Despite positive clinical data, Lisata Therapeutics Inc (LSTA)'s share price has not reacted as expected, possibly due to macroeconomic factors affecting small-cap biotech companies.
The company needs to raise substantial funds to support a phase 3 trial, which may be challenging in the current financing environment.
Lisata Therapeutics Inc (LSTA) faces limited control over timelines for investigator-initiated trials, which could affect the pace of development.
The company's current cash flow projections do not include funding for a phase 3 trial, indicating a need for additional capital.
There is a reliance on partnerships and licensing deals to fund future trials, which may not materialize as planned.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LSTA.OQ - Lisata Therapeutics Inc
Q3 2025 Lisata Therapeutics Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Lisara Therapeutics 3rd quarter 2025 financial results and business update conference call. Currently all participants are in listen-only mode. Following management prepared remarks, we will hold a Q&A session. To ask a question at that time, please press 1 on your telephone. You will then hear an automated message advising that your hand is raised. As a reminder, this call is being recorded today, Thursday, November 6th, 2025. I will now turn the call over to John Menddio, Vice President of Investor relation and corporate communication at Tisata. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.